delivery of laboratory reagents for LABFARM Spółka z ograniczoną odpowiedzialnością for the project entitled "Development of a new product - cell-based meat with an innovative production technology." implemented under Priority I Program Support for entrepreneurs, Action SMART Path, European Funds for Modern Economy 2021–2027 (FENG), part 1-2

delivery of laboratory reagents for LABFARM Spółka z ograniczoną odpowiedzialnością for the project entitled "Development of a new product - cell-based meat with an innovative production technology." implemented under Priority I Program Support for entrepreneurs, Action SMART Path, European Funds for Modern Economy 2021–2027 (FENG), part 1 1. ITS supplement for cell culture Liquid supplement for culture media, containing insulin, transferrin, and sodium selenite. Intended for enriching media used in cell cultures. Product sterile filtered, 100× concentration. 5 ml; 100× concentration; product suitable for cell culture 25 pcs. 2. Enriched ITS+1 supplement for cell culture Liquid supplement for culture media, containing insulin, transferrin, sodium selenite, bovine serum albumin (BSA) and linoleic acid. Intended for supplementing media used in cell cultures. Product sterile filtered, 100× concentration. 5 ml; 100× concentration; product suitable for cell culture 5 pcs. 3. Bleomycin sulfate Glycopeptide antibiotic with DNA-damaging activity, used as a reagent in cell biology and cell culture research. Product in powder or crystal form, with specified biological activity. 1 mg; specific activity 1.5–2.0 U/mg 1 pc. 4. Trypsin for cell dissociation Enzymatic preparation for enzymatic detachment and dissociation of adherent cells and obtaining cell suspensions. Aqueous solution at working concentration 1×, sterile filtered, suitable for cell culture applications. 100 ml; 1× concentration; sterile filtered product 20 pcs. 5. Recombinant fibroblast growth factor FGF-2 (bFGF) Recombinant protein acting as a growth factor, stimulating cell proliferation, including mesenchymal cells. Intended for use in cell cultures. Product in the form of a liquid aqueous solution, free of animal-derived components. 50 µg; concentration 0.4–0.6 mg/ml 5 pcs. delivery of laboratory reagents for LABFARM Spółka z ograniczoną odpowiedzialnością for the project entitled "Development of a new product - cell-based meat with an innovative production technology." implemented under Priority I Program Support for entrepreneurs, Action SMART Path, European Funds for Modern Economy 2021–2027 (FENG), part.2 Corticosterone Steroid compound from the corticosteroid hormone group, used as a reagent in biological and biochemical research, including studies of cellular response to hormone action. Product in crystalline powder form with a purity of not less than 95%, determined by HPLC. 1 g; purity ≥95% (HPLC); form: crystalline powder 1 pc. Ethanolamine Organic compound from the amino alcohol group, used as a chemical reagent and a component used in biological and biochemical research, including as a precursor in phospholipid biosynthesis. Product in liquid form, with a purity of not less than 98%. 100 ml; purity ≥98%; form: liquid 1 pc. Ammonium iron(III) citrate Inorganic complex compound of iron(III), used as a chemical reagent and iron source in laboratory applications. Product in powder form, of laboratory reagent grade and iron content in the range of 16.5–18.5%. 100 g; grade: reagent grade or equivalent; iron content 16.5–18.5%; form: powder 1 pc. Conditions for amending the contract: The Contracting Authority reserves the right to amend the contract concluded with the selected Tenderer in the event of at least one of the circumstances listed below, taking into account the conditions for their introduction: 1) The Contracting Authority foresees a change in the order execution deadline in the event of at least one of the circumstances listed below, taking into account the conditions for their introduction: a) force majeure preventing the timely execution of the subject of the Agreement, with the Contractor being obliged to prove the occurrence of such force majeure and indicate the impact that this event had on the course of deliveries; b) occurrence of circumstances other than force majeure, preventing the timely execution of the subject of the Agreement, which the Parties, exercising due diligence, did not foresee at the time of concluding the Agreement and are not attributable to them; c) in the event of non-transfer or late transfer to the Contractor of materials, input data and documents within the deadlines specified in the agreement or other delays on the part of the Contracting Authority, provided that the change in deadline results from circumstances that the Contracting Authority could not foresee at the stage of the proceedings, acting with due diligence; d) in the event of the need to introduce changes to the subject of the Agreement as a result of circumstances that the Contracting Authority or the Contractor could not, acting with due diligence, foresee at the time of concluding the Agreement, in particular threatening gross loss, non-performance or improper performance of the subject of the Agreement, provided that these changes do not lead to a change in the nature of the Agreement; e) Extension of administrative decision proceedings related to the subject of the contract, provided that it was not caused by reasons attributable to the Contractor. f) In the event that it becomes necessary to perform orders not covered by the Agreement, the performance of which has become necessary as a result of an unforeseeable situation, and the performance of orders covered by the Agreement will depend on the prior performance of orders not covered by the Agreement. The aforementioned changes cannot be the basis for increasing the Contractor's remuneration. Each of the aforementioned changes may be associated with a reduction in the Contractor's remuneration. 2) The Contracting Authority allows for the possibility of introducing changes to the Agreement (conditions for settling the agreement, making payments) ...